Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXSM NASDAQ:BBIO NASDAQ:EWTX NASDAQ:RGC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$226.67-0.3%$182.35$96.09▼$235.91$11.66B0.59698,692 shs430,886 shsBBIOBridgeBio Pharma$66.00+1.0%$71.36$31.77▼$84.94$12.93B1.022.78 million shs2.42 million shsEWTXEdgewise Therapeutics$31.43-0.9%$32.13$12.15▼$39.96$3.38B0.251.04 million shs1.05 million shsRGCRegencell Bioscience$27.00-2.8%$27.48$8.70▼$83.60$13.35B1.88314,562 shs97,474 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics-0.14%+5.05%+20.32%+24.06%+111.48%BBIOBridgeBio Pharma-1.22%+0.99%-14.89%-13.88%+93.03%EWTXEdgewise Therapeutics-4.14%-8.22%-7.87%+5.45%+114.61%RGCRegencell Bioscience-2.76%+1.68%-3.07%-11.97%+2,778,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$226.67-0.3%$182.35$96.09▼$235.91$11.66B0.59698,692 shs430,886 shsBBIOBridgeBio Pharma$66.00+1.0%$71.36$31.77▼$84.94$12.93B1.022.78 million shs2.42 million shsEWTXEdgewise Therapeutics$31.43-0.9%$32.13$12.15▼$39.96$3.38B0.251.04 million shs1.05 million shsRGCRegencell Bioscience$27.00-2.8%$27.48$8.70▼$83.60$13.35B1.88314,562 shs97,474 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics-0.14%+5.05%+20.32%+24.06%+111.48%BBIOBridgeBio Pharma-1.22%+0.99%-14.89%-13.88%+93.03%EWTXEdgewise Therapeutics-4.14%-8.22%-7.87%+5.45%+114.61%RGCRegencell Bioscience-2.76%+1.68%-3.07%-11.97%+2,778,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXSMAxsome Therapeutics 2.90Moderate Buy$251.2610.25% UpsideBBIOBridgeBio Pharma 2.88Moderate Buy$88.9034.38% UpsideEWTXEdgewise Therapeutics 2.89Moderate Buy$39.6724.58% UpsideRGCRegencell Bioscience 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest EWTX, RGC, BBIO, and AXSM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2026BBIOBridgeBio Pharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$82.005/15/2026BBIOBridgeBio Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)5/11/2026BBIOBridgeBio Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$100.00 ➝ $110.005/6/2026EWTXEdgewise Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$52.005/5/2026AXSMAxsome Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$280.005/5/2026AXSMAxsome Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$225.00 ➝ $255.005/5/2026AXSMAxsome Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$242.00 ➝ $302.005/5/2026AXSMAxsome Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$270.00 ➝ $290.005/5/2026AXSMAxsome Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$217.00 ➝ $242.005/5/2026AXSMAxsome Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$225.00 ➝ $255.005/5/2026AXSMAxsome Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$228.00 ➝ $310.00(Data available from 5/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXSMAxsome Therapeutics$638.50M18.37N/AN/A$1.75 per share130.23BBIOBridgeBio Pharma$502.08M25.81N/AN/A($10.77) per share-6.14EWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.93 per shareN/ARGCRegencell BioscienceN/AN/AN/AN/A$0.01 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXSMAxsome Therapeutics-$183.17M-$3.73N/A56.55N/A-26.59%-267.16%-28.53%8/3/2026 (Estimated)BBIOBridgeBio Pharma-$724.93M-$3.74N/A264.64N/A-124.42%N/A-65.81%8/4/2026 (Estimated)EWTXEdgewise Therapeutics-$167.79M-$1.66N/AN/AN/AN/A-32.55%-31.04%8/6/2026 (Estimated)RGCRegencell Bioscience-$3.58MN/AN/AN/AN/AN/AN/AN/AN/ALatest EWTX, RGC, BBIO, and AXSM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2026Q1 2026RGCRegencell BioscienceN/A-$0.0050N/A-$0.0050N/AN/A5/7/2026Q1 2026BBIOBridgeBio Pharma-$0.70-$0.84-$0.14-$0.84$178.07 million$194.52 million5/7/2026Q1 2026EWTXEdgewise Therapeutics-$0.50-$0.46+$0.04-$0.46N/AN/A5/4/2026Q1 2026AXSMAxsome Therapeutics-$0.85-$1.26-$0.41-$1.26$191.10 million$191.20 million2/26/2026Q4 2025EWTXEdgewise Therapeutics-$0.43-$0.47-$0.04-$0.47N/AN/A2/24/2026Q4 2025BBIOBridgeBio Pharma-$0.75-$1.00-$0.25-$1.00$150.71 million$154.18 million2/23/2026Q4 2025AXSMAxsome Therapeutics-$0.70-$0.56+$0.14-$0.56$191.33 million$196.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAXSMAxsome TherapeuticsN/AN/AN/AN/AN/ABBIOBridgeBio PharmaN/AN/AN/AN/AN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/ARGCRegencell BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXSMAxsome Therapeutics2.271.391.32BBIOBridgeBio PharmaN/A1.521.48EWTXEdgewise TherapeuticsN/A22.6122.61RGCRegencell BioscienceN/A1.41N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXSMAxsome Therapeutics81.49%BBIOBridgeBio Pharma99.85%EWTXEdgewise TherapeuticsN/ARGCRegencell Bioscience0.13%Insider OwnershipCompanyInsider OwnershipAXSMAxsome Therapeutics20.60%BBIOBridgeBio Pharma14.23%EWTXEdgewise Therapeutics23.20%RGCRegencell BioscienceN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXSMAxsome Therapeutics38051.46 million40.86 millionOptionableBBIOBridgeBio Pharma400195.86 million167.99 millionOptionableEWTXEdgewise Therapeutics60107.59 million82.63 millionOptionableRGCRegencell Bioscience10494.49 millionN/AN/AEWTX, RGC, BBIO, and AXSM HeadlinesRecent News About These CompaniesPomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limited and Certain Officers – RGC53 minutes ago | globenewswire.comDEADLINE ALERT for LKQ, RGC, and GLOB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders4 hours ago | globenewswire.comBronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm4 hours ago | newsfilecorp.comNRGC SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Deadline on June 23, 2026May 19 at 9:39 AM | newsfilecorp.comNRegencell Bioscience Raises $20 Million in Registered Direct Offering Led by New Institutional InvestorMay 19 at 9:31 AM | tipranks.comRGC Shareholder Alert: Regencell Bioscience Holdings Limited Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law FirmMay 19 at 9:00 AM | prnewswire.comROSEN, SKILLED INVESTOR COUNSEL, Encourages Regencell Bioscience Holdings Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action – RGCMay 18 at 8:12 PM | globenewswire.comRGC Investors Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud LawsuitMay 18 at 5:18 PM | prnewswire.comRegencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitMay 18 at 4:10 PM | prnewswire.comRGC UPCOMING DEADLINE: Levi & Korsinsky Alerts Regencell Bioscience Holdings Limited Stockholders of Securities Class Action - Contact the FirmMay 18 at 1:00 PM | globenewswire.comBronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor HarmMay 17 at 12:00 PM | globenewswire.comRGC DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Deadline on June 23, 2026May 17 at 6:40 AM | newsfilecorp.comNRegencell Bioscience (NASDAQ:RGC) Trading Up 8.8% - Should You Buy?May 17 at 4:45 AM | americanbankingnews.comRegencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitMay 15, 2026 | prnewswire.comRGC UPCOMING DEADLINE : The Gross Law Firm Alerts Regencell Bioscience Holdings Limited Stockholders of Securities Class Action - Contact the FirmMay 15, 2026 | globenewswire.comRGC UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Deadline on June 23, 2026May 15, 2026 | prnewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limited and Certain Officers - RGCMay 14, 2026 | prnewswire.comROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Regencell Bioscience Holdings Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGCMay 14, 2026 | newsfilecorp.comNDEADLINE ALERT for LKQ, RGC, and GLOB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of ShareholdersMay 14, 2026 | globenewswire.comBragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Regencell Bioscience Holdings Limited and Encourages Investors to Contact the FirmMay 13, 2026 | globenewswire.comRegencell Bioscience (NASDAQ:RGC) Trading Down 9% - What's Next?May 8, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEWTX, RGC, BBIO, and AXSM Company DescriptionsAxsome Therapeutics NASDAQ:AXSM$226.67 -0.73 (-0.32%) Closing price 04:00 PM EasternExtended Trading$226.70 +0.04 (+0.02%) As of 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.BridgeBio Pharma NASDAQ:BBIO$66.00 +0.68 (+1.04%) Closing price 04:00 PM EasternExtended Trading$66.06 +0.06 (+0.10%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Edgewise Therapeutics NASDAQ:EWTX$31.43 -0.29 (-0.91%) Closing price 04:00 PM EasternExtended Trading$31.42 0.00 (-0.02%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Regencell Bioscience NASDAQ:RGC$27.00 -0.79 (-2.84%) Closing price 04:00 PM EasternExtended Trading$27.35 +0.35 (+1.30%) As of 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas HIVE Weaponizes Power for an AI Pivot Why Home Depot’s Sell-Off Could Become a Huge Opportunity Brady Corp Wires Up a Massive AI-Powered Breakout AAPL: Forget the iPhone—Services Will Drive the Next Phase of Growth Nebius Group Pulls Back 9% After a Downgrade Despite Strong Earnings A Deep Dive Into NVIDIA’s Latest Portfolio Moves The $132 Billion Infrastructure Pivot You Might Have Missed The Pentagon's AI Pivot Supercharges Defense Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
